{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T19:57:58Z","timestamp":1764187078436,"version":"3.46.0"},"reference-count":6,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pneumologie"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die \u00c4tiologie chyl\u00f6ser Aszites ist multifaktoriell. Maligne Grunderkrankungen, Leberzirrhose, Traumata, Lymphanomalien und Mykobakteriosen sind die h\u00e4ufigsten Ursachen. Bei NSCLC wird chyl\u00f6ser Aszites bei einer peritonealen Metastasierung oder abdomineller Lymphknotenmetastasen beobachtet.<\/jats:p>\n                  <jats:p>RET-Alterationen treten bei 1\u20132% der NSCLC-Patienten auf und k\u00f6nnen seit kurzem zielgerichtet therapiert werden.<\/jats:p>\n                  <jats:p>Unsere Kasuistik zeigt, dass neue zielgerichtete Therapien die Prognose revolutionieren, uns aber vor die Herausforderung neuer und teils unbekannter Nebenwirkungen stellen.<\/jats:p>","DOI":"10.1055\/a-2095-3180","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T18:42:04Z","timestamp":1688496124000},"page":"1013-1015","source":"Crossref","is-referenced-by-count":0,"title":["Chyl\u00f6ser Aszites bei NSCLC: Nicht alles ist maligne, was maligne aussieht"],"prefix":"10.1055","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-2744","authenticated-orcid":false,"given":"Mark","family":"Uhlenbruch","sequence":"additional","affiliation":[{"name":"Pneumologie, Florence-Nightingale-Krankenhaus, D\u00fcsseldorf, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Kristin","family":"B\u00e4rmann","sequence":"additional","affiliation":[{"name":"Pneumologie, Florence-Nightingale-Krankenhaus, D\u00fcsseldorf, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Bertram","sequence":"additional","affiliation":[{"name":"Pneumologie, Florence-Nightingale-Krankenhaus, D\u00fcsseldorf, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kr\u00fcger","sequence":"additional","affiliation":[{"name":"Pneumologie, Florence-Nightingale-Krankenhaus, D\u00fcsseldorf, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/apt.14284","article-title":"Review article: the diagnostic approach and current management of chylous ascites","volume":"46","author":"B Lizaola","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"JF Gainor","year":"2021","journal-title":"The Lancet Oncology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217959","article-title":"Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis","author":"S Kassirian","year":"2022","journal-title":"Thorax"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"F Griesinger","year":"2022","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/00007611-198610000-00031","article-title":"Identification of Giardia lamblia in peritoneal fluid","volume":"79","author":"PA Drew","year":"1986","journal-title":"South Med J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jtho.2022.06.008","article-title":"Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy","volume":"17","author":"O Kalchiem-Dekel","year":"2022","journal-title":"J Thorac Oncol"}],"container-title":["Pneumologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2095-3180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T19:53:01Z","timestamp":1764186781000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2095-3180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":6,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,13]]},"published-print":{"date-parts":[[2023,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2095-3180","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0934-8387","1438-8790"],"issn-type":[{"type":"print","value":"0934-8387"},{"type":"electronic","value":"1438-8790"}],"subject":[],"published":{"date-parts":[[2023,7,4]]}}}